Edaravone and borneol for stroke patients with cancer
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a combination of two drugs, edaravone (an antioxidant) and borneol (a natural compound), can improve recovery in people who have had a stroke and also have active cancer. It may help by protecting brain cells and potentially improving motor function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have had an acute ischemic stroke (a stroke caused by a blockage) within the last 48 hours before enrollment.
- You must have a moderate to moderately severe stroke, with some weakness in your arm and leg.
- You must have active cancer, either diagnosed within the past year, with spread, or you have received cancer treatment recently.
- You must not have had a previous stroke that left you disabled, and you must not have a bleeding stroke now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
This trial tests a medicine called edaravone dexborneol to see if it helps people recover from a recent ischemic stroke (a stroke caused by a blocked blood vessel). The medicine is given within 48 hours of the stroke, and the study will compare how well it works and if it is safe.
This trial tests a new sublingual tablet (Edaravone Dexborneol) to help people recover after a small stroke caused by disease of the small blood vessels in the brain. It aims to see if the drug can improve thinking and daily function.
This study tests if a medicine called edaravone dexborneol, given within 48 hours of a stroke, can lower the risk of developing epilepsy later. It is for people who have had a stroke and are at high risk for post-stroke seizures.
This trial is testing whether a medicine called edaravone can help people who recently had a mild or moderate stroke caused by a blocked blood vessel in the brain. It aims to see if the drug improves recovery when given within the first two days after stroke symptoms start.
This study tests an under-the-tongue tablet (edaravone dexborneol) to help thinking and memory problems that can happen after an ischemic stroke. It may help people who recently had a stroke and now have trouble with attention, memory, or planning.
Hear when a new Ischemic Stroke, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.